This is not a new demonstration format. It follows our existing public case verification process, sourced from Putnam Associates' official public case description. This video is an independent teaching simulation built for executive decision support, not real correspondence, not a real client engagement, and not an endorsement, review, sponsorship, or commission by Putnam Associates. We isolate the later-stage answers first, then reconstruct only what was knowable at decision time into an educational data package for Minerva Advisor.

The case opens with a pharmaceutical company weighing investment in several AI and biomarker diagnostic solutions meant to raise the diagnosis rate for a rare disease. The real question: should the company commit capital to every candidate solution at once, or first close the highest-value evidence gaps within a defined timeline and invest in phases, watching for safety, evidence, adoption, or capacity signals that would force a stop, a scale-up, or a reversal?

This run leaves an auditable five-item work receipt. One official source was used. Four expert roles were assigned. Five confirmed facts, two inferences, and three open questions were separated out. Two investment paths were compared side by side. And three alternative explanations, plus one explicit reversal condition, were retained for executive review.

What was known at decision time: several candidate solutions could plausibly improve rare disease diagnosis. What remained unknown: which specific bottleneck in the patient journey each solution actually addresses, whether the underlying data is representative, how strong the clinical performance and bias profile really is, whether healthcare professionals would adopt the tools, and whether referral and confirmatory-testing capacity could absorb the resulting caseload.

The strongest challenge to caution: portfolio investment can be a reasonable way to diversify risk, evidence-gap caution can simply entrench the status quo, and delay itself risks missing an early adoption window. The reversal condition is explicit: if confirmatory and referral capacity data shows current capacity already exceeds the demand projected from any single solution, simultaneous limited-scale investment should proceed rather than waiting for full phased gap closure.

Held out from Minerva entirely was Putnam's own later-stage work: its review of the client's disease and patient journey knowledge base, its integration of real-world data and primary market insight, its opportunity assessment framework, its qualitative research with healthcare professionals, and the resulting recommendation that let the client proceed with further investment. This isolation tests whether Minerva can reach a sound sequencing judgment independently, without seeing Putnam's published answer.

Three advisor perspectives cross-check the same judgment. Marcus frames the real decision as which evidence gaps would actually change investment sequencing. Sofia models the consequences for clinical evidence, patient access, and the investment committee. Evelyn challenges whether closing every gap first delays access to diagnosis for patients who could benefit sooner. All three converge on the same recommendation: close the key evidence gaps within a set deadline before committing to phased investment, while Evelyn flags that any solution with an already-clear bottleneck and safety profile should not be held back by blanket caution.

Executives can verify patient journey, data, safety, clinical, and capacity evidence directly. The executive's response sets a concrete condition: submit evidence on patient journey bottlenecks, data representativeness, false positive and false negative rates, and clinical capacity within one evaluation cycle, and pause investment if the system cannot absorb new cases. The system logs this as a formal response receipt.

Minerva Advisor then shows whether that executive condition changes the underlying judgment. Betting on every solution simultaneously diversifies the risk of any single failure or delay, but it spreads resources across bottlenecks, data gaps, and adoption questions that are still unresolved. Phased investment lets decisive evidence be verified first, at the cost of possibly missing an early window of opportunity. The comparison holds both paths open for the executive to weigh directly.

The executive commits to the phased path and sets a firm deadline. Clinical evidence, patient access, and investment teams are directed to submit evidence on bottlenecks, data representativeness, clinical performance, and capacity absorption by that deadline, and the investment committee finalizes its decision only after that evidence is in hand.

Minerva does not constitute medical or investment advice, and it does not claim any official research or investment outcome has occurred. This case passed ten out of ten decision quality checks. The actual run used four model calls, delivered its first decision-ready judgment in 18.175 seconds, and completed the full result in 25.656 seconds, passing the formal 30-second first-decision and 45-second complete-result thresholds. This remains a single-case test and does not represent production service levels or real customer outcomes.